Watch IPSC. Know when insiders buy.
One email the day a filing lands. Free.
IPSC
Century Therapeutics, Inc.
2.03
−0.04 −1.93%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · insiders 50, shorts 54
Insiders, 90 days
−$1K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $367.6MP/E —DIV YIELD —FCF YIELD -23.96%REV TTM —NET INCOME −$109.8MNET CASH $39.2M52W 0.47 – 2.94SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$36.5M | −$34.5M | — | -0.17 | −$19.8M | $694K | −$20.5M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$23.7M | −$21.6M | −128.3% | -0.11 | −$25.3M | $584K | −$25.8M | Aug 12 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$20.7M | −$19.2M | — | -0.25 | −$16.1M | −$139K | −$15.9M | Mar 12 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$36.1M | −$34.4M | — | -0.40 | −$25.6M | $195K | −$25.8M | Nov 13 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$34.7M | −$32.5M | — | -0.38 | −$27.6M | $317K | −$27.9M | Aug 12 |
| Q1 2025 · Mar 31 | $109.2M | +12667.7% | — | $74.2M | $76.6M | — | 0.89 | −$34.6M | $475K | −$35.1M | Aug 12 |
| Q4 2024 · Dec 31derived | $4.2M | +1457.1% | — | −$37.3M | −$36.1M | — | -0.43 | −$24.2M | — | — | Mar 12 |
| Q3 2024 · Sep 30 | $791K | +434.5% | — | −$34.8M | −$31.2M | — | -0.37 | −$28.3M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $771K | — | — | −$34.8M | −$31.2M | — | -0.38 | −$27.3M | $265K | −$27.6M | Nov 13 |
| Q1 2024 · Mar 31 | $855K | — | — | −$31.3M | −$28.1M | — | -0.45 | −$30.2M | $539K | −$30.8M | Nov 13 |
| Q4 2023 · Dec 31derived | $268K | — | — | −$43.8M | −$39.4M | — | -0.65 | −$26.2M | $980K | −$27.2M | Mar 19 |
| Q3 2023 · Sep 30 | $148K | — | — | −$35.6M | −$32.7M | — | -0.55 | −$13.6M | $3.3M | −$16.9M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $109.2M | — | −$17.3M | −$9.6M | -8.8% | -0.14 | −$103.9M | $848K | −$104.7M | — | — |
| FY2024 · to Dec 31 | $6.6M | — | −$138.1M | −$126.6M | -1920.9% | -1.61 | −$110.1M | $154K | −$110.3M | — | — |
| FY2023 · to Dec 31 | $2.2M | — | −$146.5M | −$136.7M | -6115.1% | -2.30 | −$88.3M | $13.7M | −$102.1M | — | — |
| FY2022 · to Dec 31 | $5.2M | — | −$133.8M | −$130.9M | -2518.4% | -2.96 | $14.1M | $30.6M | −$16.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$94.9M | −$95.8M | — | -2.96 | −$89M | $45M | −$134M | — | — |
| FY2020 · to Dec 31 | — | — | −$53.9M | −$53.6M | — | -7.16 | −$41.3M | $9.8M | −$51.1M | — | — |
Every number comes from Century Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.